Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) announced its quarterly earnings data on Thursday. Here are the key takeaways from Praxis Precision Medicines’ conference call:Get Praxis Precision Medicines alerts:Ulixacaltamide and relutrigine remain on track for potential FDA decisions , with target dates around January 2027 and December 27, 2026, respectively. Praxis Precision Medicines Price PerformanceShares of NASDAQ PRAX traded down $9.40 during trading on Friday, hitting $360.76. About Praxis Precision Medicines(Get Free Report)Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. Read MoreReceive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.